COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology - Yahoo Finance

Submitted by Anonymous (not verified) on Mon, 07/17/2023 - 08:00